Natera (NTRA) Stock Price, News & Analysis

Company Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $146.34 to $153.70
• 50-Day Range: $132.23 to $160.56
• 52-Week Range: $92.01 to $183.00
• Volume: 226,604 shs
• Average Volume: 1.38 million shs
• Market Capitalization: $20.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $175.76
• Consensus Rating: Buy

Natera Stock Analysis - MarketRank™

Natera scored higher than 57% of companies evaluated by MarketBeat, and ranked 365th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Natera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Natera has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Natera are expected to grow in the coming year, from ($1.49) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Natera is -85.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Natera is -85.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Natera has a P/B Ratio of 23.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.93% of the float of Natera has been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Natera has recently increased by 7.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natera does not currently pay a dividend.

Dividend Growth

Natera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.93% of the float of Natera has been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Natera has recently increased by 7.71%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.10

News Sentiment

Natera has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Natera this week, compared to 13 articles on an average week.

Search Interest

Only 10 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,727,077.00 in company stock.

Percentage Held by Insiders

Only 7.60% of the stock of Natera is held by insiders.

Percentage Held by Institutions

99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTRA Stock Analysis - Frequently Asked Questions

How have NTRA shares performed this year?

Natera's stock was trading at $158.30 on January 1st, 2025. Since then, NTRA shares have decreased by 4.7% and is now trading at $150.93.
View the best growth stocks for 2025 here.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Thursday, February, 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The medical research company earned $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative trailing twelve-month return on equity of 26.23%.
Read the conference call transcript.

When did Natera IPO?

Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Top institutional shareholders of Natera include Bank of New York Mellon Corp (0.69%), Sumitomo Mitsui Trust Group Inc. (0.69%), Allspring Global Investments Holdings LLC (0.57%) and Principal Financial Group Inc. (0.45%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, John Fesko, Solomon Moshkevich, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Gail Boxer Marcus, Rowan E Chapman and Robert Alan Schueren.
View institutional ownership trends.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 5/01/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:NTRA
• CIK: 1604821
• Web: www.natera.com
• Phone: (650) 249-9090
• Fax: N/A
• Employees: 3,020
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $175.76
• High Stock Price Target: $251.00
• Low Stock Price Target: $125.00
• Potential Upside/Downside: +14.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-434,800,000.00
• Net Margins: -14.01%
• Pretax Margin: -13.87%
• Return on Equity: -26.23%
• Return on Assets: -14.27%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 4.39
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $1.70 billion
• Price / Sales: 12.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.37 per share
• Price / Book: 24.05

Miscellaneous

• Outstanding Shares: 135,186,000
• Free Float: 121,987,000
• Market Cap: $20.71 billion
• Optionable: Optionable
• Beta: 1.80